Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Martinetti

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|February 17, 2001
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markersA Martinetti, L Ferrari, L Celio, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 12, 1998
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levelsE Bajetta, L Ferrari, L Celio, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
The minimal effective exemestane dose for endocrine activity in advanced breast cancerE Bajetta, N Zilembo, C Noberasco, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 2, 2002
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patientsL Ferrari, A Martinetti, N Zilembo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumoursE Bajetta, L Ferrari, G Procopio, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patientsN Zilembo, L Mariani, A Martinetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) groupE Bajetta, N Zilembo, S Barni, et al.
The Pharmacogenomics Journal|March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumabF S Falvella, C Cremolini, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2018
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylationF Morano, S Corallo, M Niger, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Steroid Biochemistry and Molecular Biology|February 17, 2001
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markersA Martinetti, L Ferrari, L Celio, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 12, 1998
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levelsE Bajetta, L Ferrari, L Celio, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
The minimal effective exemestane dose for endocrine activity in advanced breast cancerE Bajetta, N Zilembo, C Noberasco, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 2, 2002
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patientsL Ferrari, A Martinetti, N Zilembo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumoursE Bajetta, L Ferrari, G Procopio, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patientsN Zilembo, L Mariani, A Martinetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) groupE Bajetta, N Zilembo, S Barni, et al.
The Pharmacogenomics Journal|March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumabF S Falvella, C Cremolini, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2018
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylationF Morano, S Corallo, M Niger, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Pageof 6